Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Industry: Biotechnology
F
Biotech is Zen Rated F and is the 139th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Sentiment
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
PTCT
PTC THERAPEUTICS INC
$3.65B79,257,01982.51%17.49%Net SellingNet Selling
AUPH
AURINIA PHARMACEUTICALS INC
$1.11B135,104,30237.02%11.36%Net BuyingNet Buying
INCY
INCYTE CORP
$12.25B193,569,93470.95%29.05%Net SellingNet Selling
EXEL
EXELIXIS INC
$12.38B272,708,28085.55%5.33%Net SellingNet Selling
CPRX
CATALYST PHARMACEUTICALS INC
$2.97B121,975,15273.80%16.05%Net BuyingNet Selling
HALO
HALOZYME THERAPEUTICS INC
$6.41B123,221,00076.77%23.23%Net SellingNet Selling
RIGL
RIGEL PHARMACEUTICALS INC
$354.50M17,872,43232.85%67.15%Net Selling
BCRX
BIOCRYST PHARMACEUTICALS INC
$2.14B209,250,27472.88%17.72%Net SellingNet Selling
PBYI
PUMA BIOTECHNOLOGY INC
$168.27M49,638,09352.31%43.75%Net Selling
BMRN
BIOMARIN PHARMACEUTICAL INC
$11.37B191,775,66586.62%1.71%Net SellingNet Selling
NAGE
NIAGEN BIOSCIENCE INC
$862.53M78,769,66213.51%86.49%Net BuyingNet Buying
CRMD
CORMEDIX INC
$832.89M67,824,65929.65%9.81%Net SellingNet Buying
ZVRA
ZEVRA THERAPEUTICS INC
$473.53M54,679,64163.82%22.65%Net SellingNet Buying
CSBR
CHAMPIONS ONCOLOGY INC
$87.80M13,826,9041.15%98.85%Net Buying
PLX
PROTALIX BIOTHERAPEUTICS INC
$132.94M79,607,1154.78%95.22%
INVA
INNOVIVA INC
$1.17B62,775,17354.59%45.41%Net SellingNet Selling
THTX
THERATECHNOLOGIES INC
$120.01M45,980,01927.61%0.00%
IMCR
IMMUNOCORE HOLDINGS PLC
$1.53B50,233,60984.45%4.33%Net BuyingNet Buying
ALNY
ALNYLAM PHARMACEUTICALS INC
$37.20B130,388,39381.76%18.24%Net SellingNet Selling
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
$1.92B72,970,96738.24%9.62%Net SellingNet Selling
ONC
BEIGENE LTD
$24.68B1,403,311,0862.11%33.07%Net SellingNet Buying
GMAB
GENMAB A
$13.16B66,197,24462.06%0.00%
HRMY
HARMONY BIOSCIENCES HOLDINGS INC
$2.01B57,424,31968.47%31.53%Net SellingNet Selling
AKBA
AKEBIA THERAPEUTICS INC
$685.48M262,635,83631.73%7.65%Net SellingNet Selling
XLO
XILIO THERAPEUTICS INC
$44.48M51,782,27339.33%60.67%Net Buying
NVO
NOVO NORDISK A S
$287.41B4,465,000,0006.94%0.00%
MNKD
MANNKIND CORP
$1.33B303,932,85233.70%66.30%Net SellingNet Selling
ZLAB
ZAI LAB LTD
$3.36B1,084,743,8605.09%1.75%Net SellingNet Selling
BDTX
BLACK DIAMOND THERAPEUTICS INC
$110.88M56,862,63565.01%34.99%Net SellingNet Selling
VCYT
VERACYTE INC
$2.29B78,314,61165.25%34.75%Net SellingNet Selling
RPRX
ROYALTY PHARMA PLC
$19.13B562,240,26950.93%17.76%Net BuyingNet Buying
STOK
STOKE THERAPEUTICS INC
$532.87M54,596,92446.03%53.97%Net SellingNet Selling
WHWK
WHITEHAWK THERAPEUTICS INC
$81.03M47,109,29332.93%67.07%Net BuyingNet Buying
VRTX
VERTEX PHARMACEUTICALS INC
$112.64B256,797,18787.24%1.51%Net SellingNet Selling
XOMA
XOMA ROYALTY CORP
$322.99M11,966,88911.81%88.19%Net SellingNet Buying
HRTX
HERON THERAPEUTICS INC
$300.55M152,563,63448.10%51.90%
KROS
KEROS THERAPEUTICS INC
$571.46M40,615,41467.26%32.74%Net BuyingNet Buying
TECH
BIO-TECHNE CORP
$7.71B156,767,29597.61%2.39%Net BuyingNet Buying
ZYME
ZYMEWORKS INC
$815.99M69,683,49247.69%52.31%Net BuyingNet Buying
TVTX
TRAVERE THERAPEUTICS INC
$1.49B88,804,81861.35%38.65%Net SellingNet Selling
FENC
FENNEC PHARMACEUTICALS INC
$188.91M27,618,7433.62%96.38%Net SellingNet Selling
TARS
TARSUS PHARMACEUTICALS INC
$1.84B42,014,23768.91%31.09%Net SellingNet Selling
VRNA
VERONA PHARMA PLC
$6.07B681,056,0228.01%52.65%Net SellingNet Selling
XERS
XERIS BIOPHARMA HOLDINGS INC
$781.56M160,155,00046.59%15.24%Net SellingNet Selling
ARGX
ARGENX SE
$34.37B60,760,95751.94%0.00%
VXRT
VAXART INC
$115.25M228,222,95311.55%54.59%Net SellingNet Selling
ARWR
ARROWHEAD PHARMACEUTICALS INC
$2.17B138,100,43569.34%9.93%Net SellingNet Selling
MDXG
MIMEDX GROUP INC
$1.04B147,702,14044.99%55.01%Net BuyingNet Buying
PVLA
PALVELLA THERAPEUTICS INC
$243.78M11,055,66523.26%56.13%Net BuyingNet Buying
UTHR
UNITED THERAPEUTICS CORP
$13.77B45,106,62386.61%13.39%Net SellingNet Buying
TGTX
TG THERAPEUTICS INC
$5.45B158,755,03654.82%45.18%Net Selling
MIRM
MIRUM PHARMACEUTICALS INC
$2.23B49,534,70946.35%53.65%Net SellingNet Selling
FTRE
FORTREA HOLDINGS INC
$399.60M90,000,00078.54%0.35%Net SellingNet Selling
IMAB
I-MAB
$73.48M187,679,4831.57%0.00%
TBPH
THERAVANCE BIOPHARMA INC
$460.01M50,001,33242.45%57.55%Net BuyingNet Selling
FHTX
FOGHORN THERAPEUTICS INC
$246.93M55,741,37329.80%14.32%Net Selling
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
$1.37B151,916,72261.32%38.68%Net SellingNet Selling
TLX
TELIX PHARMACEUTICALS LTD
$5.58B334,724,4850.01%0.00%
LGND
LIGAND PHARMACEUTICALS INC
$2.02B19,294,16816.59%83.41%Net SellingNet Buying
ATRA
ATARA BIOTHERAPEUTICS INC
$40.78M5,961,39115.98%84.02%Net BuyingNet Buying
NVAX
NOVAVAX INC
$1.09B161,970,33854.79%17.12%Net SellingNet Selling
ARQT
ARCUTIS BIOTHERAPEUTICS INC
$1.68B119,201,72474.45%25.55%Net SellingNet Selling
SEER
SEER INC
$121.86M58,868,84638.00%52.75%Net SellingNet Selling
BPMC
BLUEPRINT MEDICINES CORP
$6.57B64,582,16381.43%18.57%Net SellingNet Selling
FOLD
AMICUS THERAPEUTICS INC
$1.98B307,930,98461.29%38.71%Net SellingNet Selling
ACAD
ACADIA PHARMACEUTICALS INC
$3.73B167,361,85163.00%37.00%Net SellingNet Selling
CORT
CORCEPT THERAPEUTICS INC
$7.96B106,044,69628.59%71.41%Net BuyingNet Selling
MDGL
MADRIGAL PHARMACEUTICALS INC
$6.46B22,203,28221.91%78.09%Net SellingNet Buying
RGNX
REGENXBIO INC
$445.93M50,160,35275.34%24.66%Net SellingNet Buying
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$1.97B348,266,5810.06%0.00%
GYRE
GYRE THERAPEUTICS INC
$1.06B93,757,6021.58%98.42%Net BuyingNet Buying
SEPN
SEPTERNA INC
$437.31M44,442,49661.81%38.19%Net BuyingNet Buying
IPSC
CENTURY THERAPEUTICS INC
$48.19M86,045,03325.86%45.63%Net SellingNet Selling
KRYS
KRYSTAL BIOTECH INC
$3.77B28,898,68077.47%22.53%Net SellingNet Selling
ACOG
ALPHA COGNITION INC
$138.57M16,019,78727.77%5.15%Net Buying
AEON
AEON BIOPHARMA INC
$5.65M11,305,3675.32%94.68%
VALN
VALNEVA SE
$509.12M162,397,2020.39%0.00%
CADL
CANDEL THERAPEUTICS INC
$268.05M50,102,67936.87%31.46%Net SellingNet Selling
ACIU
AC IMMUNE SA
$171.70M100,410,3774.58%0.00%
GLUE
MONTE ROSA THERAPEUTICS INC
$244.81M61,509,82127.81%72.19%Net SellingNet Buying
CANF
CAN-FITE BIOPHARMA LTD
$9.40M2,983,181,7930.00%0.00%
CTMX
CYTOMX THERAPEUTICS INC
$163.66M80,621,29327.35%26.79%Net SellingNet Selling
LEGN
LEGEND BIOTECH CORP
$5.11B368,058,07918.24%0.00%
IKT
INHIBIKASE THERAPEUTICS INC
$149.43M74,341,54052.69%24.73%Net Buying
MESO
MESOBLAST LTD
$1.35B1,152,444,4290.27%0.00%
RARE
ULTRAGENYX PHARMACEUTICAL INC
$3.37B94,542,03581.69%16.91%Net SellingNet Selling
TLSA
TIZIANA LIFE SCIENCES LTD
$151.59M111,462,6172.66%0.00%
ARVN
ARVINAS INC
$473.71M72,991,39067.80%30.88%Net SellingNet Selling
CNTA
CENTESSA PHARMACEUTICALS PLC
$1.67B133,618,77480.19%9.91%Net SellingNet Selling
TSHA
TAYSHA GENE THERAPIES INC
$579.59M214,661,71566.93%14.58%Net BuyingNet Selling
REGN
REGENERON PHARMACEUTICALS INC
$64.17B107,965,49768.22%31.78%Net Selling
TCRX
TSCAN THERAPEUTICS INC
$70.17M56,590,62753.32%25.38%Net Buying
SLS
SELLAS LIFE SCIENCES GROUP INC
$162.64M99,777,48713.93%8.65%Net Selling
KLRS
KALARIS THERAPEUTICS INC
$65.08M18,702,4180.56%99.44%Net SellingNet Selling
ADMA
ADMA BIOLOGICS INC
$4.70B238,734,24677.55%22.45%Net SellingNet Selling
HLVX
HILLEVAX INC
$98.78M50,141,06463.46%36.54%Net Selling
PHIO
PHIO PHARMACEUTICALS CORP
$8.79M4,778,1540.10%99.90%Net Buying
NRSN
NEUROSENSE THERAPEUTICS LTD
$30.66M23,228,9410.84%0.00%
IMNM
IMMUNOME INC
$701.32M87,012,32872.20%7.69%Net BuyingNet Buying
ASMB
ASSEMBLY BIOSCIENCES INC
$102.50M7,637,55323.96%76.04%Net BuyingNet Selling

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in May 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

1. Ptc Therapeutics (NASDAQ:PTCT)


Ptc Therapeutics (NASDAQ:PTCT) is the #1 top biotech stock out of 659 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Ptc Therapeutics (NASDAQ:PTCT) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Ptc Therapeutics (NASDAQ:PTCT) has a Due Diligence Score of 35, which is 11 points higher than the biotech industry average of 24.

PTCT passed 11 out of 33 due diligence checks and has average fundamentals. Ptc Therapeutics has seen its stock return 35.2% over the past year, overperforming other biotech stocks by 112 percentage points.

Ptc Therapeutics has an average 1 year price target of $61.85, an upside of 34.42% from Ptc Therapeutics's current stock price of $46.01.

Ptc Therapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Ptc Therapeutics, 46.15% have issued a Strong Buy rating, 15.38% have issued a Buy, 23.08% have issued a hold, while 0% have issued a Sell rating, and 15.38% have issued a Strong Sell.

2. Aurinia Pharmaceuticals (NASDAQ:AUPH)


Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #2 top biotech stock out of 659 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 62, which is 38 points higher than the biotech industry average of 24.

AUPH passed 20 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 41.94% over the past year, overperforming other biotech stocks by 119 percentage points.

3. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the #3 top biotech stock out of 659 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Incyte (NASDAQ:INCY) is: Value: A, Growth: A, Momentum: D, Sentiment: B, Safety: C, Financials: B, and AI: B.

Incyte (NASDAQ:INCY) has a Due Diligence Score of 47, which is 23 points higher than the biotech industry average of 24.

INCY passed 15 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock return 11.34% over the past year, overperforming other biotech stocks by 89 percentage points.

Incyte has an average 1 year price target of $73.50, an upside of 16.1% from Incyte's current stock price of $63.31.

Incyte stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Incyte, 10% have issued a Strong Buy rating, 0% have issued a Buy, 90% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 6 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Jade Biosciences (NASDAQ:JBIO)


Jade Biosciences (NASDAQ:JBIO) has an annual dividend yield of 32.68%, which is 27 percentage points higher than the biotech industry average of 6.07%.

Jade Biosciences's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

2. Dominari Holdings (NASDAQ:DOMH)


Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 5.39%, which is -1 percentage points lower than the biotech industry average of 6.07%.

Dominari Holdings's dividend payout ratio of -7.1% indicates that its high dividend yield might not be sustainable for the long-term.

3. Novo Nordisk (Ozempic) (NYSE:NVO)


Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.5%, which is -4 percentage points lower than the biotech industry average of 6.07%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.2% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.42% in the last day, and up 3.39% over the last week. Inozyme Pharma was the among the top gainers in the biotechnology industry, gaining 178.17% yesterday.

Inozyme shares are trading higher after the company announced BioMarin will acquire the company for about $270 million.

What are the most undervalued biotech stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

1. Puma Biotechnology (NASDAQ:PBYI)


Puma Biotechnology (NASDAQ:PBYI) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -23.13% in the past year. It has overperformed other stocks in the biotech industry by 54 percentage points.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 19.65% in the past year. It has overperformed other stocks in the biotech industry by 97 percentage points.

3. Jazz Pharmaceuticals (NASDAQ:JAZZ)


Jazz Pharmaceuticals (NASDAQ:JAZZ) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Jazz Pharmaceuticals has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Jazz Pharmaceuticals's stock has dropped -1.37% in the past year. It has overperformed other stocks in the biotech industry by 76 percentage points.

Are biotech stocks a good buy now?

55.64% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 109.82% over the next year.

2.65% of biotech stocks have a Zen Rating of A (Strong Buy), 3.97% of biotech stocks are rated B (Buy), 38.63% are rated C (Hold), 34% are rated D (Sell), and 20.75% are rated F (Strong Sell).

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is -154.88x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.